What question did this study set out to answer?

This study aims to evaluate the effectiveness of pembrolizumab as a second-line therapy for advanced urothelial carcinoma.

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

View Full Paper

Ask AI

Bookmark

This study aims to evaluate the effectiveness of pembrolizumab as a second-line therapy for advanced urothelial carcinoma.
Utilized pembrolizumab as second-line therapy for platinum-refractory patients.
Compared treatment outcomes to chemotherapy.
Conducted under KEYNOTE-045 trial (NCT02256436).
Patients receiving pembrolizumab experienced longer overall survival by approximately 3 months.
Pembrolizumab had a lower rate of treatment-related adverse events compared to chemotherapy.

No takes yet. Share an insight, caveat, or question.

Randomized trial shows improved overall survival in advanced urothelial carcinoma, suggesting pembrolizumab may be a better choice than chemotherapy.

Bellmunt et al. (2017) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial shows improved overall survival in advanced urothelial carcinoma, suggesting pembrolizumab may be a better choice than chemotherapy.